Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

NAMS

+ Watchlist+ Portfolio

NewAmsterdam Pharma Company N.V.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$19.74
52-Week Range
$17.90 – $42.21
Market Cap
$2.34B
P/E (TTM)
—
EPS (TTM)
-1.69
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.71
PEG Ratio
—
Return on Equity
-30.16%
Return on Assets
-19.79%
Gross Margin
100.00%
Operating Margin
-900.07%
Profit Margin
0.00%
Current Ratio
11.76
Debt/Equity
0.00
Total Debt
$76.00K
Free Cash Flow
$-98.63M
Revenue Growth
5406.90%
Earnings Growth
—
Enterprise Value
$1.74B

Market Snapshot

About

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company developing oral therapies for cardiovascular disease. The company focuses on lipid-lowering treatments targeting patients with high cholesterol who remain at risk despite current therapies.